IN SWEDISHToday, the results of the STHLM3 study were published in the prestigious scientific journal The Lancet Oncology. The study shows that the STHLM3 test is better at finding dangerous prostate cancers compared to today’s diagnosis with PSA.
In practical terms, the STHLM3 test offers the possibility of earlier detection of dangerous prostate cancer, while at the same time fewer people are exposed to the discomfort and side effects of tissue tests and subsequent treatment. In Stockholm, this would mean that about half of the men who today need to take tissue samples can avoid this with the STHLM3 test without missing dangerous cancer.
“It is, of course, incredibly gratifying that we have had such a good impact on our research,” says Professor Henrik Grönberg, scientific leader of STHLM3. “Many men are worried about prostate cancer. Being able to present a better test for prostate cancer is of course extremely satisfying as it can help many men ”.
Prostate cancer is Sweden’s most common cancer. Stockholm County Council, together with Karolinska Institutet, has carried out STHLM3 – one of the world’s largest studies of prostate cancer. The results of the STHLM3 study were published in the prestigious scientific journal The Lancet Oncology on November 9, 2015.